{"id":"half-amount-low-molecular-weight-heparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL4594468","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller chains with a molecular weight of 3,000–10,000 Da. At half the standard dose, it provides anticoagulation through enhanced binding to antithrombin III, which then inactivates activated clotting factors, particularly factor Xa. This reduced-dose formulation may be used for thromboprophylaxis or treatment of thromboembolic conditions where standard dosing is not required.","oneSentence":"Low molecular weight heparin at reduced dosage inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:21.583Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in surgical or medical patients"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT04946929","phase":"PHASE3","title":"Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-07-31","conditions":"Hepatic Artery Thrombosis, Liver Transplant; Complications, Pediatric Disease","enrollment":50},{"nctId":"NCT02658838","phase":"PHASE4","title":"The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2015-04","conditions":"LOVASTATIN/TICAGRELOR [VA Drug Interaction]","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Half amount enoxaparin"],"phase":"marketed","status":"active","brandName":"half amount low molecular weight heparin","genericName":"half amount low molecular weight heparin","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low molecular weight heparin at reduced dosage inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa. Used for Thromboprophylaxis in surgical or medical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}